Bionano Genomics Reports Q4 Revenue of $8M, Sets FY Outlook at $30-33M
Summary
Bionano Genomics announced its Q4 financial results, reporting revenue of $8 million, operating expenses of $11.9 million ($9.7 million adjusted), and a gross margin of 43%. The company also provided its full-year revenue outlook, projecting $30-33 million. This is a significant financial update, offering investors crucial insight into the company's recent performance and future expectations. As a primary financial disclosure, these figures are highly material for assessing the company's trajectory and will be closely scrutinized by the market.
At the time of this announcement, BNGO was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.9M. The 52-week trading range was $1.06 to $5.50. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.